

## Results of Annual General Meeting

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") today held an Annual General Meeting of Members at the offices of BDO Australia - Melbourne, Collins Square, Tower 4, Level 18, 727 Collins St, Docklands VIC 3008.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

### Authority

This announcement was authorised for release by Alessandra Gauvin, Company Secretary of Neurotech International Limited.

For further information contact us via [info@neurotechinternational.com](mailto:info@neurotechinternational.com)

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

# Disclosure of Proxy Votes

## Neurotech International Limited

Annual General Meeting

Thursday, 20 November 2025



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution   | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes          |                    |         |                      | Poll Results (if applicable) |                    |         | Results |
|--|--|--|----------------------|--------------------|---------|----------------------|------------------------------|--------------------|---------|---------|
|  |  |  | FOR                  | AGAINST            | ABSTAIN | PROXY'S DISCRETION   | FOR                          | AGAINST            | ABSTAIN | OUTCOME |
| 1 ADOPTION OF REMUNERATION REPORT  | P  | 65,790,871   | 62,599,787<br>95.15% | 2,969,237<br>4.51% | 165,526 | 221,847<br>0.34%     | 62,821,634<br>95.49%         | 2,969,237<br>4.51% | 165,526 | -       |
| 2 RE-ELECTION OF MARK DAVIES   | P  | 101,348,172  | 64,476,557<br>63.62% | 957,783<br>0.95%   | 281,101 | 35,913,832<br>35.44% | 101,423,722<br>99.06%        | 957,783<br>0.94%   | 281,101 | Carried |
| 3 APPROVAL OF 7.1A MANDATE   | P  | 101,567,473  | 61,076,033<br>60.13% | 4,558,308<br>4.49% | 61,800  | 35,933,132<br>35.38% | 98,042,498<br>95.56%         | 4,558,308<br>4.44% | 61,800  | Carried |
| 4 RATIFICATION OF PRIOR ISSUE OF OPTIONS TO ANTIFILIPPIS INVESTMENTS PTY LTD | P  | 101,463,747  | 61,008,607<br>60.13% | 4,541,308<br>4.48% | 165,526 | 35,913,832<br>35.40% | 97,955,772<br>95.57%         | 4,541,308<br>4.43% | 165,526 | Carried |

